Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Illumina Inc., solvency ratios (quarterly data)
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Illumina Inc. debt to equity ratio improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
| Debt to equity (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Illumina Inc. debt to equity ratio (including operating lease liability) improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Illumina Inc. debt to capital ratio improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
| Debt to capital (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Illumina Inc. debt to capital ratio (including operating lease liability) improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Illumina Inc. debt to assets ratio improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
| Debt to assets (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Illumina Inc. debt to assets ratio (including operating lease liability) improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Illumina Inc. financial leverage ratio decreased from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Illumina Inc. interest coverage ratio deteriorated from Q1 2021 to Q2 2021 but then improved from Q2 2021 to Q3 2021 exceeding Q1 2021 level. |
Debt to Equity
Illumina Inc., debt to equity calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Build-to-suit lease liability | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 22) | 21) | 21) | 144) | 124) | 124) | 192) | 223) | 178) | —) | —) | |||||||
| Convertible senior notes, current portion | —) | —) | 488) | 511) | 507) | 503) | 499) | —) | —) | —) | 631) | 1,107) | 1,107) | 625) | 620) | 10) | 2) | 5) | 1) | 1) | 1) | 1) | —) | |||||||
| Term notes | 993) | 992) | 992) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Convertible senior notes, excluding current portion | 694) | 687) | 680) | 673) | 666) | 659) | 652) | 1,141) | 1,131) | 1,120) | 1,112) | 890) | 860) | 723) | 710) | 1,182) | 1,180) | 1,169) | 1,055) | 1,048) | 1,041) | 1,031) | 1,023) | |||||||
| Total debt | 1,687) | 1,679) | 2,160) | 1,184) | 1,173) | 1,162) | 1,151) | 1,141) | 1,131) | 1,120) | 1,743) | 1,997) | 1,989) | 1,369) | 1,351) | 1,336) | 1,306) | 1,298) | 1,248) | 1,272) | 1,220) | 1,032) | 1,023) | |||||||
| Total Illumina stockholders’ equity | 10,593) | 5,180) | 4,922) | 4,694) | 4,700) | 4,563) | 4,635) | 4,613) | 4,439) | 4,332) | 3,985) | 3,758) | 3,503) | 3,257) | 3,008) | 2,749) | 2,855) | 2,715) | 2,551) | 2,197) | 2,240) | 2,056) | 1,991) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to equity1 | 0.16 | 0.32 | 0.44 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.26 | 0.44 | 0.53 | 0.57 | 0.42 | 0.45 | 0.49 | 0.46 | 0.48 | 0.49 | 0.58 | 0.54 | 0.50 | 0.51 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 5.96 | 6.53 | 6.24 | 6.58 | 5.70 | 5.94 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 4.57 | 3.98 | 3.50 | 3.51 | 3.13 | 3.21 | 3.36 | 3.09 | 2.73 | 2.84 | 3.05 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 1.20 | 1.23 | 1.23 | 1.34 | 0.90 | 0.95 | 0.94 | 0.91 | 1.41 | 1.56 | 0.40 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.54 | 0.48 | 0.50 | 0.53 | 0.57 | 0.62 | 0.84 | 0.72 | 0.54 | 0.32 | 0.30 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 2.20 | 2.56 | 2.35 | 2.94 | 3.51 | 3.99 | 5.60 | 5.88 | 4.50 | 5.68 | 6.44 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 1.29 | 1.53 | 1.59 | 1.73 | 1.68 | 1.34 | 1.09 | 1.09 | 1.19 | 1.15 | 1.21 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.48 | 0.48 | 0.51 | 0.56 | 0.59 | 0.48 | 0.45 | 0.47 | 0.50 | 0.48 | 0.50 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.74 | 0.80 | 1.16 | 1.26 | 0.98 | 1.12 | 1.07 | 1.02 | 0.97 | 0.96 | 0.94 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 0.02 | 0.05 | 0.04 | 0.04 | 0.04 | 0.02 | 0.02 | 0.03 | 0.04 | 0.03 | 0.03 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.53 | 0.56 | 0.58 | 0.63 | 0.97 | 0.99 | 0.80 | 0.83 | 0.81 | 0.78 | 0.77 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.16 | 0.18 | 0.23 | 0.24 | 0.27 | 0.24 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.56 | 0.51 | 0.53 | 0.63 | 0.66 | 0.71 | 0.70 | 0.60 | 0.58 | 0.66 | 0.66 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Debt to equity = Total debt ÷ Total Illumina stockholders’ equity
= 1,687 ÷ 10,593 = 0.16
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Illumina Inc. debt to equity ratio improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
Debt to Equity (including Operating Lease Liability)
Illumina Inc., debt to equity (including operating lease liability) calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Build-to-suit lease liability | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 22) | 21) | 21) | 144) | 124) | 124) | 192) | 223) | 178) | —) | —) | |||||||
| Convertible senior notes, current portion | —) | —) | 488) | 511) | 507) | 503) | 499) | —) | —) | —) | 631) | 1,107) | 1,107) | 625) | 620) | 10) | 2) | 5) | 1) | 1) | 1) | 1) | —) | |||||||
| Term notes | 993) | 992) | 992) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Convertible senior notes, excluding current portion | 694) | 687) | 680) | 673) | 666) | 659) | 652) | 1,141) | 1,131) | 1,120) | 1,112) | 890) | 860) | 723) | 710) | 1,182) | 1,180) | 1,169) | 1,055) | 1,048) | 1,041) | 1,031) | 1,023) | |||||||
| Total debt | 1,687) | 1,679) | 2,160) | 1,184) | 1,173) | 1,162) | 1,151) | 1,141) | 1,131) | 1,120) | 1,743) | 1,997) | 1,989) | 1,369) | 1,351) | 1,336) | 1,306) | 1,298) | 1,248) | 1,272) | 1,220) | 1,032) | 1,023) | |||||||
| Operating lease liabilities, excluding current portion | 784) | 704) | 664) | 671) | 678) | 681) | 696) | 695) | 691) | 698) | 718) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Total debt (including operating lease liability) | 2,471) | 2,383) | 2,824) | 1,855) | 1,851) | 1,843) | 1,847) | 1,836) | 1,822) | 1,818) | 2,461) | 1,997) | 1,989) | 1,369) | 1,351) | 1,336) | 1,306) | 1,298) | 1,248) | 1,272) | 1,220) | 1,032) | 1,023) | |||||||
| Total Illumina stockholders’ equity | 10,593) | 5,180) | 4,922) | 4,694) | 4,700) | 4,563) | 4,635) | 4,613) | 4,439) | 4,332) | 3,985) | 3,758) | 3,503) | 3,257) | 3,008) | 2,749) | 2,855) | 2,715) | 2,551) | 2,197) | 2,240) | 2,056) | 1,991) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to equity (including operating lease liability)1 | 0.23 | 0.46 | 0.57 | 0.40 | 0.39 | 0.40 | 0.40 | 0.40 | 0.41 | 0.42 | 0.62 | 0.53 | 0.57 | 0.42 | 0.45 | 0.49 | 0.46 | 0.48 | 0.49 | 0.58 | 0.54 | 0.50 | 0.51 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||||||
| Moderna Inc. | 0.03 | 0.06 | 0.06 | 0.08 | 0.08 | 0.06 | 0.09 | 0.11 | 0.04 | 0.03 | 0.03 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Total Illumina stockholders’ equity
= 2,471 ÷ 10,593 = 0.23
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Illumina Inc. debt to equity ratio (including operating lease liability) improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
Debt to Capital
Illumina Inc., debt to capital calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Build-to-suit lease liability | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 22) | 21) | 21) | 144) | 124) | 124) | 192) | 223) | 178) | —) | —) | |||||||
| Convertible senior notes, current portion | —) | —) | 488) | 511) | 507) | 503) | 499) | —) | —) | —) | 631) | 1,107) | 1,107) | 625) | 620) | 10) | 2) | 5) | 1) | 1) | 1) | 1) | —) | |||||||
| Term notes | 993) | 992) | 992) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Convertible senior notes, excluding current portion | 694) | 687) | 680) | 673) | 666) | 659) | 652) | 1,141) | 1,131) | 1,120) | 1,112) | 890) | 860) | 723) | 710) | 1,182) | 1,180) | 1,169) | 1,055) | 1,048) | 1,041) | 1,031) | 1,023) | |||||||
| Total debt | 1,687) | 1,679) | 2,160) | 1,184) | 1,173) | 1,162) | 1,151) | 1,141) | 1,131) | 1,120) | 1,743) | 1,997) | 1,989) | 1,369) | 1,351) | 1,336) | 1,306) | 1,298) | 1,248) | 1,272) | 1,220) | 1,032) | 1,023) | |||||||
| Total Illumina stockholders’ equity | 10,593) | 5,180) | 4,922) | 4,694) | 4,700) | 4,563) | 4,635) | 4,613) | 4,439) | 4,332) | 3,985) | 3,758) | 3,503) | 3,257) | 3,008) | 2,749) | 2,855) | 2,715) | 2,551) | 2,197) | 2,240) | 2,056) | 1,991) | |||||||
| Total capital | 12,280) | 6,859) | 7,082) | 5,878) | 5,873) | 5,725) | 5,786) | 5,754) | 5,570) | 5,452) | 5,728) | 5,755) | 5,492) | 4,626) | 4,359) | 4,085) | 4,161) | 4,013) | 3,799) | 3,469) | 3,460) | 3,088) | 3,014) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to capital1 | 0.14 | 0.24 | 0.30 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.21 | 0.30 | 0.35 | 0.36 | 0.30 | 0.31 | 0.33 | 0.31 | 0.32 | 0.33 | 0.37 | 0.35 | 0.33 | 0.34 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 0.86 | 0.87 | 0.86 | 0.87 | 0.85 | 0.86 | 1.12 | 1.14 | 1.27 | 1.30 | 1.27 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 0.82 | 0.80 | 0.78 | 0.78 | 0.76 | 0.76 | 0.77 | 0.76 | 0.73 | 0.74 | 0.75 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.55 | 0.55 | 0.55 | 0.57 | 0.47 | 0.49 | 0.48 | 0.48 | 0.59 | 0.61 | 0.28 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.35 | 0.32 | 0.33 | 0.35 | 0.37 | 0.38 | 0.46 | 0.42 | 0.35 | 0.24 | 0.23 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.69 | 0.72 | 0.70 | 0.75 | 0.78 | 0.80 | 0.85 | 0.85 | 0.82 | 0.85 | 0.87 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 0.56 | 0.60 | 0.61 | 0.63 | 0.63 | 0.57 | 0.52 | 0.52 | 0.54 | 0.54 | 0.55 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.33 | 0.32 | 0.34 | 0.36 | 0.37 | 0.33 | 0.31 | 0.32 | 0.33 | 0.33 | 0.33 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.42 | 0.44 | 0.54 | 0.56 | 0.50 | 0.53 | 0.52 | 0.50 | 0.49 | 0.49 | 0.48 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 0.02 | 0.05 | 0.03 | 0.04 | 0.04 | 0.02 | 0.02 | 0.03 | 0.04 | 0.03 | 0.03 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.35 | 0.36 | 0.37 | 0.39 | 0.49 | 0.50 | 0.45 | 0.45 | 0.45 | 0.44 | 0.43 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.14 | 0.15 | 0.18 | 0.20 | 0.21 | 0.20 | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.36 | 0.34 | 0.35 | 0.39 | 0.40 | 0.42 | 0.41 | 0.37 | 0.37 | 0.40 | 0.40 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Debt to capital = Total debt ÷ Total capital
= 1,687 ÷ 12,280 = 0.14
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Illumina Inc. debt to capital ratio improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
Debt to Capital (including Operating Lease Liability)
Illumina Inc., debt to capital (including operating lease liability) calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Build-to-suit lease liability | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 22) | 21) | 21) | 144) | 124) | 124) | 192) | 223) | 178) | —) | —) | |||||||
| Convertible senior notes, current portion | —) | —) | 488) | 511) | 507) | 503) | 499) | —) | —) | —) | 631) | 1,107) | 1,107) | 625) | 620) | 10) | 2) | 5) | 1) | 1) | 1) | 1) | —) | |||||||
| Term notes | 993) | 992) | 992) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Convertible senior notes, excluding current portion | 694) | 687) | 680) | 673) | 666) | 659) | 652) | 1,141) | 1,131) | 1,120) | 1,112) | 890) | 860) | 723) | 710) | 1,182) | 1,180) | 1,169) | 1,055) | 1,048) | 1,041) | 1,031) | 1,023) | |||||||
| Total debt | 1,687) | 1,679) | 2,160) | 1,184) | 1,173) | 1,162) | 1,151) | 1,141) | 1,131) | 1,120) | 1,743) | 1,997) | 1,989) | 1,369) | 1,351) | 1,336) | 1,306) | 1,298) | 1,248) | 1,272) | 1,220) | 1,032) | 1,023) | |||||||
| Operating lease liabilities, excluding current portion | 784) | 704) | 664) | 671) | 678) | 681) | 696) | 695) | 691) | 698) | 718) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Total debt (including operating lease liability) | 2,471) | 2,383) | 2,824) | 1,855) | 1,851) | 1,843) | 1,847) | 1,836) | 1,822) | 1,818) | 2,461) | 1,997) | 1,989) | 1,369) | 1,351) | 1,336) | 1,306) | 1,298) | 1,248) | 1,272) | 1,220) | 1,032) | 1,023) | |||||||
| Total Illumina stockholders’ equity | 10,593) | 5,180) | 4,922) | 4,694) | 4,700) | 4,563) | 4,635) | 4,613) | 4,439) | 4,332) | 3,985) | 3,758) | 3,503) | 3,257) | 3,008) | 2,749) | 2,855) | 2,715) | 2,551) | 2,197) | 2,240) | 2,056) | 1,991) | |||||||
| Total capital (including operating lease liability) | 13,064) | 7,563) | 7,746) | 6,549) | 6,551) | 6,406) | 6,482) | 6,449) | 6,261) | 6,150) | 6,446) | 5,755) | 5,492) | 4,626) | 4,359) | 4,085) | 4,161) | 4,013) | 3,799) | 3,469) | 3,460) | 3,088) | 3,014) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to capital (including operating lease liability)1 | 0.19 | 0.32 | 0.36 | 0.28 | 0.28 | 0.29 | 0.28 | 0.28 | 0.29 | 0.30 | 0.38 | 0.35 | 0.36 | 0.30 | 0.31 | 0.33 | 0.31 | 0.32 | 0.33 | 0.37 | 0.35 | 0.33 | 0.34 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||||||
| Moderna Inc. | 0.03 | 0.06 | 0.06 | 0.07 | 0.07 | 0.05 | 0.08 | 0.10 | 0.04 | 0.03 | 0.03 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= 2,471 ÷ 13,064 = 0.19
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Illumina Inc. debt to capital ratio (including operating lease liability) improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
Debt to Assets
Illumina Inc., debt to assets calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Build-to-suit lease liability | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 22) | 21) | 21) | 144) | 124) | 124) | 192) | 223) | 178) | —) | —) | |||||||
| Convertible senior notes, current portion | —) | —) | 488) | 511) | 507) | 503) | 499) | —) | —) | —) | 631) | 1,107) | 1,107) | 625) | 620) | 10) | 2) | 5) | 1) | 1) | 1) | 1) | —) | |||||||
| Term notes | 993) | 992) | 992) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Convertible senior notes, excluding current portion | 694) | 687) | 680) | 673) | 666) | 659) | 652) | 1,141) | 1,131) | 1,120) | 1,112) | 890) | 860) | 723) | 710) | 1,182) | 1,180) | 1,169) | 1,055) | 1,048) | 1,041) | 1,031) | 1,023) | |||||||
| Total debt | 1,687) | 1,679) | 2,160) | 1,184) | 1,173) | 1,162) | 1,151) | 1,141) | 1,131) | 1,120) | 1,743) | 1,997) | 1,989) | 1,369) | 1,351) | 1,336) | 1,306) | 1,298) | 1,248) | 1,272) | 1,220) | 1,032) | 1,023) | |||||||
| Total assets | 15,063) | 8,675) | 8,755) | 7,585) | 7,404) | 7,248) | 7,261) | 7,316) | 7,089) | 6,973) | 7,390) | 6,959) | 6,759) | 5,851) | 5,542) | 5,257) | 5,046) | 4,858) | 4,598) | 4,281) | 4,228) | 3,985) | 3,794) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to assets1 | 0.11 | 0.19 | 0.25 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.24 | 0.29 | 0.29 | 0.23 | 0.24 | 0.25 | 0.26 | 0.27 | 0.27 | 0.30 | 0.29 | 0.26 | 0.27 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 0.54 | 0.56 | 0.57 | 0.57 | 0.58 | 0.58 | 0.74 | 0.75 | 0.65 | 0.65 | 0.65 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 0.58 | 0.55 | 0.52 | 0.52 | 0.53 | 0.53 | 0.52 | 0.50 | 0.50 | 0.52 | 0.52 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.40 | 0.41 | 0.41 | 0.43 | 0.36 | 0.36 | 0.36 | 0.36 | 0.43 | 0.45 | 0.17 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.29 | 0.26 | 0.27 | 0.28 | 0.30 | 0.31 | 0.38 | 0.35 | 0.29 | 0.19 | 0.18 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.35 | 0.35 | 0.35 | 0.36 | 0.39 | 0.39 | 0.42 | 0.39 | 0.40 | 0.41 | 0.42 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 0.41 | 0.44 | 0.45 | 0.46 | 0.48 | 0.43 | 0.40 | 0.40 | 0.42 | 0.41 | 0.42 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.19 | 0.19 | 0.19 | 0.20 | 0.22 | 0.19 | 0.18 | 0.18 | 0.19 | 0.19 | 0.20 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.28 | 0.29 | 0.34 | 0.35 | 0.32 | 0.34 | 0.33 | 0.31 | 0.31 | 0.32 | 0.31 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.22 | 0.23 | 0.25 | 0.26 | 0.35 | 0.36 | 0.31 | 0.31 | 0.31 | 0.30 | 0.29 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.11 | 0.13 | 0.15 | 0.16 | 0.17 | 0.15 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.29 | 0.28 | 0.28 | 0.31 | 0.33 | 0.35 | 0.34 | 0.30 | 0.30 | 0.33 | 0.33 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Debt to assets = Total debt ÷ Total assets
= 1,687 ÷ 15,063 = 0.11
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Illumina Inc. debt to assets ratio improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
Debt to Assets (including Operating Lease Liability)
Illumina Inc., debt to assets (including operating lease liability) calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Build-to-suit lease liability | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 22) | 21) | 21) | 144) | 124) | 124) | 192) | 223) | 178) | —) | —) | |||||||
| Convertible senior notes, current portion | —) | —) | 488) | 511) | 507) | 503) | 499) | —) | —) | —) | 631) | 1,107) | 1,107) | 625) | 620) | 10) | 2) | 5) | 1) | 1) | 1) | 1) | —) | |||||||
| Term notes | 993) | 992) | 992) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Convertible senior notes, excluding current portion | 694) | 687) | 680) | 673) | 666) | 659) | 652) | 1,141) | 1,131) | 1,120) | 1,112) | 890) | 860) | 723) | 710) | 1,182) | 1,180) | 1,169) | 1,055) | 1,048) | 1,041) | 1,031) | 1,023) | |||||||
| Total debt | 1,687) | 1,679) | 2,160) | 1,184) | 1,173) | 1,162) | 1,151) | 1,141) | 1,131) | 1,120) | 1,743) | 1,997) | 1,989) | 1,369) | 1,351) | 1,336) | 1,306) | 1,298) | 1,248) | 1,272) | 1,220) | 1,032) | 1,023) | |||||||
| Operating lease liabilities, excluding current portion | 784) | 704) | 664) | 671) | 678) | 681) | 696) | 695) | 691) | 698) | 718) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Total debt (including operating lease liability) | 2,471) | 2,383) | 2,824) | 1,855) | 1,851) | 1,843) | 1,847) | 1,836) | 1,822) | 1,818) | 2,461) | 1,997) | 1,989) | 1,369) | 1,351) | 1,336) | 1,306) | 1,298) | 1,248) | 1,272) | 1,220) | 1,032) | 1,023) | |||||||
| Total assets | 15,063) | 8,675) | 8,755) | 7,585) | 7,404) | 7,248) | 7,261) | 7,316) | 7,089) | 6,973) | 7,390) | 6,959) | 6,759) | 5,851) | 5,542) | 5,257) | 5,046) | 4,858) | 4,598) | 4,281) | 4,228) | 3,985) | 3,794) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to assets (including operating lease liability)1 | 0.16 | 0.27 | 0.32 | 0.24 | 0.25 | 0.25 | 0.25 | 0.25 | 0.26 | 0.26 | 0.33 | 0.29 | 0.29 | 0.23 | 0.24 | 0.25 | 0.26 | 0.27 | 0.27 | 0.30 | 0.29 | 0.26 | 0.27 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||||||
| Moderna Inc. | 0.02 | 0.03 | 0.02 | 0.03 | 0.04 | 0.05 | 0.07 | 0.08 | 0.03 | 0.03 | 0.02 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= 2,471 ÷ 15,063 = 0.16
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Illumina Inc. debt to assets ratio (including operating lease liability) improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
Financial Leverage
Illumina Inc., financial leverage calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Total assets | 15,063) | 8,675) | 8,755) | 7,585) | 7,404) | 7,248) | 7,261) | 7,316) | 7,089) | 6,973) | 7,390) | 6,959) | 6,759) | 5,851) | 5,542) | 5,257) | 5,046) | 4,858) | 4,598) | 4,281) | 4,228) | 3,985) | 3,794) | |||||||
| Total Illumina stockholders’ equity | 10,593) | 5,180) | 4,922) | 4,694) | 4,700) | 4,563) | 4,635) | 4,613) | 4,439) | 4,332) | 3,985) | 3,758) | 3,503) | 3,257) | 3,008) | 2,749) | 2,855) | 2,715) | 2,551) | 2,197) | 2,240) | 2,056) | 1,991) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Financial leverage1 | 1.42 | 1.67 | 1.78 | 1.62 | 1.58 | 1.59 | 1.57 | 1.59 | 1.60 | 1.61 | 1.85 | 1.85 | 1.93 | 1.80 | 1.84 | 1.91 | 1.77 | 1.79 | 1.80 | 1.95 | 1.89 | 1.94 | 1.91 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 10.99 | 11.77 | 10.98 | 11.51 | 9.80 | 10.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 7.91 | 7.25 | 6.70 | 6.69 | 5.90 | 6.10 | 6.50 | 6.17 | 5.45 | 5.50 | 5.91 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 2.98 | 3.01 | 2.99 | 3.13 | 2.50 | 2.61 | 2.59 | 2.52 | 3.25 | 3.44 | 2.29 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 1.90 | 1.82 | 1.87 | 1.92 | 1.92 | 1.97 | 2.22 | 2.05 | 1.89 | 1.66 | 1.64 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 6.21 | 7.42 | 6.79 | 8.27 | 9.10 | 10.25 | 13.35 | 15.07 | 11.20 | 13.91 | 15.32 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 3.13 | 3.45 | 3.56 | 3.76 | 3.49 | 3.10 | 2.71 | 2.74 | 2.87 | 2.79 | 2.86 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 2.55 | 2.54 | 2.62 | 2.76 | 2.65 | 2.51 | 2.53 | 2.65 | 2.67 | 2.55 | 2.54 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 2.61 | 2.72 | 3.37 | 3.62 | 3.08 | 3.28 | 3.24 | 3.26 | 3.10 | 3.04 | 2.99 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 2.07 | 2.41 | 3.31 | 2.86 | 1.69 | 1.18 | 1.26 | 1.35 | 1.27 | 1.26 | 1.25 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 2.37 | 2.43 | 2.31 | 2.44 | 2.74 | 2.77 | 2.56 | 2.65 | 2.62 | 2.62 | 2.64 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 1.37 | 1.42 | 1.48 | 1.56 | 1.59 | 1.59 | 1.30 | 1.34 | 1.33 | 1.35 | 1.36 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 1.90 | 1.84 | 1.88 | 2.00 | 2.01 | 2.06 | 2.05 | 1.97 | 1.93 | 2.02 | 2.01 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Financial leverage = Total assets ÷ Total Illumina stockholders’ equity
= 15,063 ÷ 10,593 = 1.42
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Illumina Inc. financial leverage ratio decreased from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
Interest Coverage
Illumina Inc., interest coverage calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Net income attributable to Illumina stockholders | 317) | 185) | 147) | 257) | 179) | 47) | 173) | 239) | 234) | 296) | 233) | 210) | 199) | 209) | 208) | 68) | 163) | 128) | 367) | 124) | 129) | 120) | 90) | |||||||
| Add: Net income attributable to noncontrolling interest | —) | —) | —) | —) | —) | —) | —) | —) | —) | (3) | (9) | (13) | (11) | (9) | (11) | (10) | (11) | (8) | (19) | (16) | (12) | (4) | (2) | |||||||
| Add: Income tax expense | 103) | 22) | 22) | 41) | 36) | 118) | 5) | 30) | 36) | 53) | 9) | 12) | 44) | 32) | 24) | 166) | 23) | 21) | 155) | 27) | 37) | 41) | 28) | |||||||
| Add: Interest expense | 14) | 16) | 19) | 16) | 11) | 11) | 11) | 11) | 11) | 15) | 15) | 20) | 15) | 11) | 11) | 11) | 10) | 8) | 8) | 8) | 8) | 8) | 9) | |||||||
| Earnings before interest and tax (EBIT) | 434) | 223) | 188) | 314) | 226) | 176) | 189) | 280) | 281) | 361) | 248) | 229) | 247) | 243) | 232) | 235) | 185) | 149) | 511) | 143) | 163) | 165) | 124) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Interest coverage1 | 17.83 | 15.34 | 15.86 | 18.47 | 19.80 | 21.05 | 23.15 | 22.50 | 18.34 | 16.69 | 15.85 | 16.68 | 19.94 | 20.81 | 20.03 | 29.19 | 28.79 | 29.69 | 30.05 | 17.91 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Interest Coverage, Competitors2 | ||||||||||||||||||||||||||||||
| Amgen Inc. | 6.46 | 6.48 | 7.64 | 7.44 | 7.62 | 7.62 | 7.85 | 8.09 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 28.74 | 25.87 | 21.54 | 17.35 | 16.90 | 20.00 | 25.33 | 31.44 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 10.06 | 7.61 | 2.93 | 2.70 | 2.83 | 0.41 | 5.90 | 6.19 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 94.27 | 87.06 | 73.87 | 83.07 | 96.82 | 81.36 | 81.56 | 55.49 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 139.74 | 104.12 | 68.20 | 67.97 | 72.22 | 108.12 | 90.22 | 81.43 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 19.94 | 19.52 | 17.58 | 14.07 | 10.78 | 7.93 | 7.66 | 7.02 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Interest coverage
= (EBITQ3 2021
+ EBITQ2 2021
+ EBITQ1 2021
+ EBITQ4 2020)
÷ (Interest expenseQ3 2021
+ Interest expenseQ2 2021
+ Interest expenseQ1 2021
+ Interest expenseQ4 2020)
= (434 + 223 + 188 + 314)
÷ (14 + 16 + 19 + 16)
= 17.83
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Illumina Inc. interest coverage ratio deteriorated from Q1 2021 to Q2 2021 but then improved from Q2 2021 to Q3 2021 exceeding Q1 2021 level. |